The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Before CagriSema, Novo Nordisk already had Wegovy, which has been quite successful as a weight loss drug. Zepbound (tirzepatide ... Nordisk's performance with charts, breakdowns, 30-year financial ...

Relying solely on BMI to diagnose obesity may be outdated, say global experts. A new report calls for a more comprehensive ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Over the past two years rocketing sales of Wegovy and its main rival, Zepbound ... spending on weight-loss drugs will surge from $15bn this year to $94bn by 2030 (see chart 1).

Before CagriSema, Novo Nordisk already had Wegovy, which has been quite successful as a weight loss drug. Zepbound (tirzepatide ... now and deep dive into Novo Nordisk's performance with charts, ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Simultaneously, the market for weight-loss drugs is experiencing a revolutionary shift, driven by advances in treatments like Ozempic, Wegovy, and Zepbound—three drugs that are showing ...